Drug Type Small molecule drug |
Synonyms Citarinostat (USAN), ACY 241, ACY-241 + [2] |
Target |
Mechanism HDAC6 inhibitors(Histone deacetylase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H26ClN5O3 |
InChIKeyVLIUIBXPEDFJRF-UHFFFAOYSA-N |
CAS Registry1316215-12-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | US | 24 Jun 2016 | |
Smoldering Multiple Myeloma | Phase 1 | US | 07 Mar 2017 | |
Smoldering Multiple Myeloma | Phase 1 | US | 07 Mar 2017 | |
Unresectable Melanoma | Phase 1 | US | 30 Sep 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 22 Dec 2015 | |
Refractory Multiple Myeloma | Phase 1 | US | 07 May 2015 | |
Refractory Multiple Myeloma | Phase 1 | FR | 07 May 2015 | |
Refractory Multiple Myeloma | Phase 1 | DE | 07 May 2015 | |
Refractory Multiple Myeloma | Phase 1 | GR | 07 May 2015 | |
Refractory Multiple Myeloma | Phase 1 | ES | 07 May 2015 |
Phase 1 | 20 | paclitaxel+citarinostat | rutxyvwuec(xagfuxpnst) = citarinostat 360 mg/day eueakgpdea (xkbfkmdipn ) View more | Positive | 04 Jun 2018 | ||
Phase 1 | 40 | llapzkzacv(ywcnkdsvhq) = 1 grade 4 thrombocytopenia at 360 mg xbexafdyyb (ulbgrxnbpm ) View more | Positive | 02 Dec 2016 |